Abstract
Several purinergic receptors have been identified on platelets which are involved in hemostatic and thrombotic processes. The aim of the present study was to investigate the effects of uridine and its nucleotides on platelet aggregation and hemostasis in platelet-rich plasma (PRP) and whole blood. The effects of uridine, UMP, UDP, and UTP at different final concentrations (1 to 1000 µM) on platelet aggregation were studied using an aggregometer. In PRP samples, platelet aggregation was induced by ADP, collagen and epinephrine 3 min after addition of uridine, UMP, UDP, UTP and saline (as a control). All thromboelastogram experiments were performed at 1000 µM final concentrations of uridine and its nucleotides in whole blood. UDP and UTP were also tested in thromboelastogram with PRP. Our results showed that UDP, and especially UTP, inhibited ADP- and collagen-induced aggregation in a concentration-dependent manner. In whole blood thromboelastogram experiments, UDP stimulated clot formation while UTP suppressed clot formation. When thromboelastogram experiments were repeated with PRP, UTP’s inhibitory effect on platelets was confirmed, while UDP’s stimulated clot forming effect disappeared. Collectively, our data showed that UTP inhibited platelet aggregation in a concentration-dependent manner and suppressed clot formation. On the other hand, UDP exhibited distinct effects on whole blood or PRP in thromboelastogram. These data suggest that the difference on effects of UTP and UDP might have arisen from the different receptors that they stimulate and warrant further investigation with regard to their in vivo actions on platelet aggregation and hemostasis.
Highlights
UDP and UTP exhibit different effects on platelet aggregation and hemostasis.
UTP inhibits platelet aggregation and hemostasis both in whole blood and PRP samples.
UDP has distinct effects on hemostasis in whole blood or PRP in thromboelastogram.
The findings suggest the involvement of different receptors stimulated by UDP or UTP in the observed effects.
Similar content being viewed by others
References
Davi G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357(24):2482–2494. https://doi.org/10.1056/NEJMra071014
WHO-Global hearts initiative. [accessed 2020 September 12]. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Burnstock G (2017) Purinergic Signalling: therapeutic developments. Front Pharmacol 8:661. https://doi.org/10.3389/fphar.2017.00661
Cansev M, Orhan F, Yaylagul EO, Isik E, Turkyilmaz M, Aydin S, Gumus A, Sevinc C, Coskun N, Ulus IH, Wurtman RJ (2015) Evidence for the existence of pyrimidinergic transmission in rat brain. Neuropharmacology 91:77–86. https://doi.org/10.1016/j.neuropharm
Kügelgen Iv, Hoffmann K (2016) Pharmacology and structure of P2Y receptors. Neuropharmacology 104:50–61. https://doi.org/10.1016/j.neuropharm.2015.10.030
North RA (2016) P2X receptors. Philos Trans R Soc Lond B Biol Sci 371:20150427. https://doi.org/10.1098/rstb.2015.0427
Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K (2018) Pharmacology of Adenosine Receptors: the state of the art. Physiol Rev 98:1591–1625. https://doi.org/10.1152/physrev.00049.2017
Murugappan S, Kunapuli SP (2006) The role of ADP receptors in platelet function. Front Biosci 11:1977–1986. https://doi.org/10.2741/1939
Burnstock G (2015) Blood cells: an historical account of the roles of purinergic signaling. Purinergic Signal 11:411–434. https://doi.org/10.1007/s11302-015-9462-7
Gachet C, Hechler B (2020) Platelet purinergic receptors in thrombosis and inflammation. Hämostaseologie 40:145–152. https://doi.org/10.1055/a-1113-0711
Koupenova M, Ravid K (2018) Biology of platelet purinergic receptors and implications for platelet heterogeneity. Front Pharmacol 9:37. https://doi.org/10.3389/fphar.2018.00037
Johnston-Cox HA, Ravid K (2011) Adenosine and blood platelets. Purinergic Signal 7:357–365. https://doi.org/10.1007/s11302-011-9220-4
Harden TK, Sesma JI, Fricks IP, Lazarowski ER (2010) Signalling and pharmacological properties of the P2Y14 receptor. Acta Physiol (Oxf) 199(2):149–160. https://doi.org/10.1111/j.1748-1716.2010.02116.x
Dovlatova N, Wijeyeratne YD, Fox SC, Manolopoulos P, Johnson AJ, White AE, Latif ML, Ralevic V, Heptinstall S (2008) Detection of P2Y14 protein in platelets and investigation of the role of P2Y14 in platelet function in comparison with the EP3 receptor. Thromb Haemost 100:261–270 PMID: 18690346
Kauffenstein G, Hechler B, Cazenave J-P, Gachet C (2004) Adenine triphosphate nucleotides are antagonists at the P2Y12 receptor. J Thromb Haemost 2:1980–1988. https://doi.org/10.1111/j.1538-7836.2004.00926.x
Aslam M, Sedding D, Koshty A, Santoso S, Schulz R, Hamm C, Gündüz D (2013) Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y1 and P2Y12 receptors. Thromb Res 132:548–557. https://doi.org/10.1016/j.thromres.2013.08.021
Chang H, Yanachkov IB, Michelson AD, Li Y, Barnard MR, Wright GE, Frelinger AL (2010) Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1receptors. Thromb Res 125:159–165. https://doi.org/10.1016/j.thromres.2009.11.006
Högberg C, Gidlöf O, Deflorian F, Jacobson KA, Abdelrahman A, Miüller CE, Olde B, Erlinge D (2012) Farnesyl pyrophosphate is an endogenous antagonist to ADP stimulated P2Y12 receptor-mediated platelet aggregation. Thromb Haemost 108(1):119–132. https://doi.org/10.1160/TH11-10-0749
Traut TW (1994) Physiological concentrations of purine and pyrimidines. Mol Cell Biochem 140:1–22. https://doi.org/10.1007/BF00928361
Wurtman RJ, Regan M, Ulus I, Yu L (2000) Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol 60(7):989–992. https://doi.org/10.1016/s0006-2952(00)00436-6
Goetz U, Da Prada M, Pletscher A (1971) Adenine-, guanine- and uridine-5’-phosphonucleotides in blood platelets and storage organelles of various species. J Pharmacol Exp Ther 178:210–215 PMID: 5087398
Löfgren L, Pehrsson S, Hagglund G, Tjellström H, Nylander S (2018) Accurate measurement of endogenous adenosine in human blood. PLoS ONE 13(10):e0205707. https://doi.org/10.1371/journal.pone.0205707
Costa-Filho RC, Bozza FA (2017) Platelets: an outlook from biology through evidence-based achievements in critical care. Ann Transl Med 5(22):449. https://doi.org/10.21037/atm.2017.11.04
Wurtman RJ, Cansev M, Sakamoto T, Ulus IH (2009) Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr 29:59–87. https://doi.org/10.1146/annurev-nutr-080508-141059
Valeri CR, Srey R, Tilahun D, Ragno G (2004) In vitro effects of poly-N-acetyl glucosamine on the activation of platelets in platelet-rich plasma with and without red blood cells. J Trauma 57(1 Suppl):S22–S25. https://doi.org/10.1097/01.ta.0000136744.12440.47
Gosselin RC, Estacio EE, Song JY, Dwyre DM (2016) Verifying the performance characteristics of the TEG5000 thromboelastogram in the clinical laboratory. Int J Lab Hematol 38(2):183–192. https://doi.org/10.1111/ijlh.12464
Wang X, Chen D (2018) Purinergic regulation of neutrophil function. Front Immunol 9:399. https://doi.org/10.3389/fimmu.2018.00399
Swystun LL, Liaw PC (2016) The role of leukocytes in thrombosis. Blood 128(6):753–762. https://doi.org/10.1182/blood-2016-05-718114
Noubouossie DF, Reeves BN, Strahl BD, Key NS (2019) Neutrophils: back in the thrombosis spotlight. Blood133(20):2186–2197. doi: https://doi.org/10.1182/blood-2018-10-862243
Amison RT, Arnold S, O’Shaughnessy BG, Cleary SJ, Ofoedu J, Idzko M, Page CP, Pitchford SC (2017) Lipopolysaccharide (LPS) induced pulmonary neutrophil recruitment and platelet activation is mediated via the P2Y1 and P2Y14 receptors in mice. Pulm Pharmacol Ther 45:62–68. https://doi.org/10.1016/j.pupt.2017.05.005
Barrett MO, Sesma JI, Ball CB, Jayasekara PS, Jacobson KA, Lazarowski ER, Harden TK (2013) A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose–stimulated chemotaxis of human neutrophils. Mol Pharmacol 84:41–49. https://doi.org/10.1124/mol.113.085654
Sil P, Hayes CP, Reaves BJ, Breen P, Quinn S, Sokolove J, Rada B (2017) P2Y6 receptor antagonist MRS2578 inhibits neutrophil activation and aggregated neutrophil extracellular trap formation induced by gout-associated monosodium urate crystals. J Immunol 198:428–442. https://doi.org/10.4049/jimmunol.1600766
Brinkmann V, Zychlinsky A (2012) Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol 198(5):773–783. https://doi.org/10.1083/jcb.201203170
Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD (2010) Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 107:15880–15885. https://doi.org/10.1073/pnas.1005743107
Massberg S, Grahl L, Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB et al (2010) Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 16:887–896. https://doi.org/10.1038/nm.2184
Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, Monestier M, Toy P, Werb Z, Looney MR (2012) Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 122(7):2661–2671. https://doi.org/10.1172/JCI61303
Gündüz D, Tanislav C, Sedding D, Parahuleva M, Santoso S, Troidl C, Hamm CW, Aslam M (2017) Uridine triphosphate thio analogues inhibit platelet P2Y12 receptor and aggregation. Int J Mol Sci 18:269. https://doi.org/10.3390/ijms18020269
Funding
This work was supported by the Bursa Uludağ University Scientific Research Projects Unit under Grant BUAP(T) − 2015/2.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Arı, M., Sağdilek, E., Kılınç, E. et al. Effects of uridine and nucleotides on hemostasis parameters. J Thromb Thrombolysis 55, 626–633 (2023). https://doi.org/10.1007/s11239-023-02793-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-023-02793-y